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Abstract 55 
 56 
These updated EBMT guidelines review the clinical evidence, registry activity 57 
and mechanisms of action of haematopoietic stem cell transplantation (HSCT) 58 
in multiple sclerosis (MS) and other immune-mediated neurological diseases 59 
and provide recommendations for patient selection, transplant technique, 60 
follow-up and future development. The major focus is on autologous HSCT, 61 
which has been used in MS for over two decades and is currently the fastest 62 
growing indication of this treatment in Europe, where there is increasing 63 
evidence to support its use in highly active relapsing remitting MS failing to 64 
respond to disease modifying therapies. Autologous HSCT may have a 65 
potential role in the treatment of the progressive forms of MS with significant 66 
inflammatory component and other immune-mediated neurological diseases, 67 
including chronic inflammatory demyelinating polyneuropathy, neuromyelitis 68 
optica, myasthenia gravis and stiff person syndrome. Allogeneic HSCT should 69 
only be considered where potential risks are justified. Compared with other 70 
immunomodulatory treatments, HSCT is associated with greater short-term 71 
risks and requires close interspeciality collaboration between transplant 72 
physicians and neurologists with a special interest in these neurological 73 
conditions before, during and after treatment in accredited HSCT centres. 74 
Other experimental cell therapies are developmental indications for these 75 
diseases and patients should only be treated on clinical trials. 76 
  77 
 78 
  79 
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1. Introduction 80 
1.1 Multiple sclerosis 81 
Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of 82 
the central nervous system (CNS) and the leading cause of non-traumatic neurological 83 
disability of young adults1. It affects approximately 2.3 million people worldwide with a 84 
prevalence of 1 in 700 adults2. Following diagnosis, patients rapidly fall out of employment, 85 
with recent data indicating that after 5 years only 25% of people are still working. As a 86 
result, MS has an economic impact disproportionate to its prevalence related to the high 87 
cost of disease modifying therapies (DMTs), the direct and indirect costs of relapses and 88 
associated costs of benefits and personal care3.  89 
 90 
MS is typically a biphasic disease. In the intial phase, the illness usually runs a relapsing 91 
remitting (RRMS) course4 characterized by repeated episodes of inflammation within the 92 
CNS, often accompanied by Gadolinium (Gd) enhancing lesions on magnetic resonance 93 
imaging (MRI) and characterized pathologically by inflammatory infiltrates rich in T and B 94 
cells and macrophages1. The ensuing secondary progressive MS (SPMS) phase is 95 
characterized by slow accumulation of disability with a progressive decline in inflammation, 96 
and increasing axonal and neuronal loss5. Other clinical variants included primary 97 
progressive MS (PPMS) where patients experience disability progression from disease 98 
onset4, and aggressive (or malignant) MS where the illness runs a fulminant course with 99 
rapid accumulation of significant disability6. The Expanded Disability Status Scale (EDSS)7 100 
is the most commonly used method of assessing disability progression in MS, whilst MRI 101 
is used to assess disese activity and atrophy.  102 
 103 
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Inflammatory forms of MS respond to immunomodulation with DMTs which aim to achieve 104 
a state of No Evidence of Disease Activity (NEDA), reflected by absence of clinical 105 
relapses, disability progression and MRI disease activity8. In the majority of patients with 106 
RRMS, the illness can be controlled by currently approved DMTs and various professional 107 
guidelines are available with recommendations for their sequential use based on baseline 108 
disease activity and response to treatment9. However, a significant proportion of patients 109 
continue to have clinical and/or MRI disease activity despite the use of DMTs10. Whilst 110 
more efficacious DMTs may lead in many but not in all patients to relatively high levels of 111 
disease control in the short term reflected by NEDA, these agents are expensive and have 112 
significant risks including infusion-associated reactions, secondary autoimmunity and 113 
infections including progressive multifocal leukoencephalopathy (PML). Unfortunately, the 114 
treatment options are very limited once the neurodegenerative phase of SPMS is 115 
established11. Equally, PPMS is very challenging to treat although some patients with 116 
clinical and MR scan activity may respond to immunomodulation12. 117 
 118 
There is increasing published evidence, including randomised controlled trials (RCTs) 119 
which convincingly demonstrates robust clinical efficacy of autologous HSCT (aHSCT) in 120 
patients with highly active MS, along with improved safety with markedly reduced levels of 121 
non-relapse mortality (NRM) risk which supports its incorporation into standard MS 122 
treatment algorithms13-21.   123 
 124 
1.2 Other neuroinflammatory diseases 125 
Autoimmunity and neuro-inflammation may affect the CNS and peripheral nervous 126 
systems (PNS) in a range of diseases including chronic inflammatory demyelinating 127 
polyneuropathy (CIDP), neuromyelitis optica (NMO), myasthenia gravis (MG), stiff person 128 
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syndrome (SPS), and autoimmune encephalopathies17. There are also patients with 129 
systemic autoimmune diseases, where there is a significant neuro-inflammatory 130 
component managed in neurology clinics. Whilst many patients respond well to standard 131 
treatment pathways, responses may be inadequate leading to the development of 132 
significant and potentially permanent disability consequent upon degenerative changes. In 133 
such settings aHSCT has been reported as a means of intensive 134 
immunomodulation13,18,19,21.  135 
 136 
2. Activity of HSCT in autoimmune diseases: the EBMT Registry and the EBMT 137 
activity survey 138 
The activity of HSCT and cell therapy in Europe is reflected by two complementary but 139 
different database analyses; the EBMT Registry, for which full EBMT membership 140 
mandates reporting of detailed data, and the broader EBMT activity survey, which 141 
captures annual HSCT activity, both from all EBMT members (full and associate) and 142 
other non-EBMT centres. Severe treatment-resistant autoimmune diseases, predominantly 143 
MS, have been treated with both aHSCT and allogeneic HSCT (allo-HSCT) for over two 144 
decades and are currently the fastest growing indication group for HSCT in the annual 145 
EBMT activity survey21-23.  146 
 147 
The EBMT Registry is currently the largest database worldwide for HSCT with over half a 148 
million registrations, including over 3000 patients treated for autoimmune and inflammatory 149 
diseases. The current status of the EBMT Registry in relation to MS and other immune-150 
related neurological diseases is summarized in Table 1 and Figures 1-3, alongside the 151 
increasing activity in other autoimmune diseases (ADs). There have been various degrees 152 
of uptake by national neurological and HSCT communities across EBMT, but overall the 153 
growing evidence base is reflected by a progressive increase in registrations, particularly 154 
  
 
7
in the last 5 years. Over time there has been a shift from SPMS to RRMS (figure 3.1). 155 
Paediatric patients (<18 years) undergoing aHSCT for MS are rare, with only 28 156 
registrations to date. 157 
 158 
Non-relapse mortality (NRM), an unfamiliar concept to most neurologists, is used 159 
interchangeably in these guidelines with the closely-related treatment-related mortality 160 
(TRM) parameter, and is an important consideration for HSCT in immune-mediated 161 
neurological diseases, which may be severely disabling but only rarely immediately life-162 
threatening. In MS NRM (and TRM) have significantly improved significantly in EBMT 163 
registry data21, with recently reported levels of 0.2%, similar to levels derived from meta-164 
analysis of published studies16, and this may be attributed to greater experience, patient 165 
selection, transplant technique and accreditation13-21. 166 
 167 
It is not possible to provide meaningful estimates of the activity trends and NRM risks of 168 
aHSCT in the rarer immune-mediated neurological diseases given small numbers, 169 
heterogeneity and varying degrees of disability and co-morbidity. The published literature 170 
includes some outcomes and may be open to selection bias. These rare indications are 171 
the subject of ongoing EBMT registry-based analyses. Likewise, the numbers of patients 172 
who have received allo-HSCT for neurological ADs are low21, even in a recent EBMT 173 
analysis of allo-HSCT24. 174 
 175 
3. EBMT guidelines and recommendations 176 
Multi-disciplinary guidelines across a wide range of ADs were published by the EBMT 177 
ADWP in 1997 and 2012 to cover general principles of patient selection, stem cell 178 
collection, graft manipulation, conditioning regimens, supportive care and follow-up25-26. 179 
These included guidelines for MS and other immune-mediated neurological diseases, but, 180 
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given the increase in evidence, updates are now warranted. The EBMT has recently 181 
published a broad update of all malignant and non-malignant indications for HSCT, which 182 
covers the main adult and paediatric ADs but provides limited detail27.  183 
 184 
The aim of these updated guidelines is to provide a more detailed and comprehensive 185 
review of the evidence, registry data and mechanisms of action and to provide specific 186 
recommendations for patient selection, treatment procedures, follow-up and future 187 
development of HSCT in patients with MS and other immune-mediated neurological 188 
diseases. As previously, the guideline authorship group includes clinicians from relevant 189 
professional groups active in the ADWP, including nursing, statistical and data 190 
management representation, all with experience in HSCT for neurological ADs. The 191 
principal target audience is transplant physicians, nurses and their teams as well as 192 
neurologists working with transplant teams, or considering referral of patients. The 193 
guideline is not primarily targetted at patients, families and non-specialist health 194 
professional carers, although it supplements recently published information from the 195 
EBMT28. Evidence was sourced from PubMed searches of original observations and key 196 
reviews and, where relevant, recent EBMT congress presentations, with a view to updating 197 
the previous EBMT 2012 guidelines26. As per other EBMT guidelines and 198 
recommendations26,27, evidence for indications is systematically classified in four 199 
categories where HSCT should be considered (S/CO/D/GNR - see table 2 and related 200 
footnotes). Strength of the evidence supporting the assignment of a particular category is 201 
graded (levels I, II, and III) based on consideration of health benefits, side effects and risks 202 
and balanced against the non-HSCT options. Each recommendation provides potential for 203 
auditing clinical practice. The guideline also considers the resource implications and other 204 
issues relevant to implementation of HSCT in this area. Other than EBMT support there is 205 
no funding body supporting these guidelines, commercial or otherwise, and conflicts within 206 
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the authorship are disclosed. The EBMT ADWP plan future updates according to 207 
developments in evidence base and clinical practice. 208 
 209 
4. Clinical evidence for aHSCT in MS and immune mediated neurological diseases 210 
4.1. Multiple sclerosis (MS) 211 
Although the first patients to be treated with aHSCT for MS were in 199529-30, there is now 212 
growing evidence from large registry studies and two prospective comparative trials to 213 
support the efficacy of aHSCT in patients with highly active MS, with long-term clinical and 214 
MRI remissions observed in a majority of patients with acceptable safety. These include 1) 215 
a small phase II RCT which, despite some methodological limitations, demonstrated the 216 
superiority of aHSCT with the ‘BEAM-ATG’ intermediate intensity conditioning regimen in 217 
suppressing MRI activity and clinical relapses compared with mitoxantrone31; 2) single arm 218 
prospective studies demonstrating aHSCT with cyclophosphamide-ATG (‘Cy-ATG’), 219 
‘BEAM-ATG’, or high-intensity (‘BuCy-ATG’) conditioning regimens induced sustained 220 
clinical remissions and suppression of MRI activity in patients with active MS32-35.  221 
 222 
Similar outcomes were reflected in other large retrospective series15,36-38. Long-term 223 
outcomes have been analysed in a large cohort of patients treated before 2006, which 224 
included a mixture of RRMS, SPMS and PPMS15. Systematic analyses of NEDA rates 225 
following aHSCT support durable clinical remission in a high proportion of patients with 226 
RRMS, suggesting that potential benefit could exceed that seen after approved DMTs 227 
including those considered to be highly efficacious39,40. 228 
 229 
The evidence-base has been significantly boosted by the recent publication of interim 230 
results of the first large RCT phase III study, MIST, comparing aHSCT using a non-231 
myeloablative regimen (Cy-ATG) versus FDA approved DMTs with no deaths or serious 232 
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toxicity in the HSCT group41.  Moreover, 30 patients who were originally randomized into 233 
the DMT arm were crossed over to the transplant arm after reaching the primary endpoint 234 
of the trial, with significant fall in EDSS after receiving aHSCT42.  235 
The interim results of MIST provide evidence that aHSCT is safe and has superior efficacy 236 
compared with many currently available DMTs, although, for historical reasons, MIST did 237 
not include alemtuzumab, ocrelizumab or cladribine in the control arm. Therefore, there 238 
remains a need for comparative studies that randomize patients to aHSCT versus these 239 
agents43-45. Even so, it would appear that aHSCT still offers clear advantages with NEDA 240 
rates of 66-93% compared with alemtuzumab, natalizumab or ocrelizumab. The area 241 
needs to be systematically resolved via prospective RCTs (see section 9.1.3).  242 
 243 
4.2 Patient selection for aHSCT in MS 244 
Undoubtedly aHSCT is more intensive and has greater short-term toxicities than any DMT. 245 
It is used in MS primarily as an anti-inflammatory and immunomodulatory treatment, which 246 
makes the presence of significant clinical and MRI evidence of an active inflammatory 247 
component, along with fitness to tolerate it, a pre-requisite. Younger patients, shorter 248 
duration of disease, lower EDSS scores, active inflammatory disease, and absence of 249 
other co-morbidity have been associated with favourable outcomes15,16,18-20,27,39,40,46-48. Any 250 
decision to proceed must assess the balance of benefits and risks particularly in terms of 251 
reversibility or stabilisation of disability and other neurological features. 252 
 253 
4.2.1 Highly active relapsing remitting MS failing DMT 254 
In line with MIST and other studies, patients with highly active RRMS failing at least one 255 
line of DMT may be considered for aHSCT, with treatment failure defined by the 256 
documented occurrence of at least two clinical relapses or one clinical relapse and the 257 
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presence of MRI activity at an independent time point in the previous 12 months 258 
16,18.20,41,42. 259 
4.2.2 ’Aggressive’ MS 260 
About 4-14% of MS patients have ‘aggressive’ disease and experience an accelerated (3 261 
to 4 times faster) disease course6,49. Various terminologies have been used to describe 262 
this ‘aggressive’ phenotype, including ‘malignant’, 'fulminant’ and ’Marburg variant’. The 263 
‘therapeutic window’ in a patient with ‘aggressive’ MS is significantly shorter and, in this 264 
relatively rare context, aHSCT is highly effective at inducing prolonged clinical 265 
remissions50-52. Thus, deteriorating patients with ‘aggressive’ disease at risk of irreversible 266 
disability should be rapidly considered for aHSCT, even if a full course of DMT has not 267 
been completed to formally establish treatment failure 20,26,50.    268 
4.2.3 Progressive MS with active inflammatory component 269 
Registry studies and other cohort analyses have repeatedly shown that aHSCT is more 270 
efficacious in patients with RRMS than SPMS or PPMS13-16,18,20,26,27. Even so, several 271 
reports support the association of Gd-enhancement with favorable outcomes15,16,31,53. 272 
More recent data from the siponimod trial11 support a role for ongoing inflammation in the 273 
chronic progressive phase of MS and aHSCT may therefore be justified at this stage 274 
provided that disease activity has been documented. 275 
In PPMS, registry-based studies have supported very limited benefit with aHSCT, if at all, 276 
and therefore recommendations have previously discouraged its use26. However, some 277 
studies have suggested that immunomodulation may provide benefit54,55. More recently, 278 
treatment with ocrelizumab has been associated with lower rate of clinical and MRI 279 
progression12. Given the poor prognosis, the support from registry data15,16 and the limited 280 
treatment options, very occasional patients with high levels of persistent inflammatory 281 
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activity with rapidly accumulating disability may be considered. Prospective studies are 282 
warranted to explore the potential of aHSCT in PPMS. 283 
4.2.4 Paediatric MS 284 
MS is rare disease in children, but its consequences are particularly severe as disability 285 
may be life-long56. In a cohort of 21 patients under 18 years, aHSCT was well tolerated 286 
and associated with improvements of EDSS scores in 81% of patients with progression 287 
free survival (PFS) of 100% at 3-5 years, hence potentially more efficacious in children 288 
than in adults17. Given a greater potential for late effects, a reasonable approach is to try 289 
other less toxic treatments first, e.g. interferon or fingolimod57, and reserve aHSCT for 290 
patients with breakthrough inflammation. 291 
Recommendations 292 
• Autologous HSCT should be offered to patients with RRMS with high 293 
clinical and MRI inflammatory disease activity (at least 2 clinical relapses, 294 
or one clinical relapse with Gd-enhancing or new T2 MRI lesions at a 295 
separate time point, in the previous 12 months) despite the use of one or 296 
more lines of approved DMTs. Evidence best supports treatment in 297 
patients who are able to ambulate independently (EDSS 5.5 or less), who 298 
are younger than 45 years and have disease duration less than 10 years 299 
(level S/I).  300 
• Patients with ‘aggressive’ MS, who develop severe disability in the 301 
previous 12 months, are suitable candidates for aHSCT. Given the 302 
potential for irreversible disability, such patients may be considered even 303 
before failing a full course of DMT (level CO/II). 304 
• Patients with SPMS should be considered for aHSCT, preferably in a 305 
prospective clinical trial, only when inflammatory activity is still evident 306 
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(clinical relapses and Gd-enhancing or new T2 MRI lesions) with 307 
documented disability progression in the previous 12 months (level CO/II).  308 
• Patients with PPMS should be considered for aHSCT, preferably in a 309 
prospective clinical trial, only when inflammatory activity is evident (Gd-310 
enhancing and new T2 MRI lesions) with documented evident disability 311 
progression in the previous 12 months (level CO/II).   312 
• Paediatric patients with MS who have breakthough inflammatory disease 313 
with less toxic treatments may be considered for aHSCT (level CO/II). 314 
 315 
4.3 Autologous HSCT in other immune-mediated neurological diseases 316 
4.3.1 Chronic inflammatory demyelinating polyneuropathy (CIDP) 317 
CIDP is an immune-mediated disease targeting peripheral nerves. To prevent disability, 318 
immunosuppressive treatments should be initiated before irreversible axonal damage has 319 
occurred. There is limited experience with aHSCT in CIDP with a total of twenty patients 320 
reported (4 received BEAM-based, and the remainder cyclophosphamide-based protocols) 321 
of whom 90% improved, and 35% experienced further relapses58-62. Recently, a large 322 
single centre experience was reported with high levels of response63. 323 
4.3.2 Myasthenia Gravis (MG) 324 
Myasthenia gravis (MG), an immune-mediated disease targeting the neuromuscular 325 
junction, has been treated with aHSCT, with ten patients described in the literature. Seven 326 
were treated at a single centre with high-intensity conditioning regimens containing total 327 
body irradiation (TBI) or busulphan, with good tolerance and durable remission in all 328 
patients after a median follow-up of 40 months64. Similar outcomes in three further patients 329 
using cyclophosphamide-based conditioning were reported 65-67.  330 
 331 
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4.3.3 Stiff person syndrome (SPS) 332 
Stiff person syndrome (SPS) is a rare immune-mediated neurological disorder 333 
characterised by muscle rigidity, spasms, brain stem hyperexcitability and high glutamic 334 
acid decarboxylase (GAD)-specific antibodies. Autologous HSCT has successfully been 335 
used to treat limited numbers of SPS patients68,69. Most patients respond to aHSCT, 336 
although responses are variable and may depend on the variant and duration of SPS. 337 
 338 
4.3.4 Neuromyelitis optica (NMO)  339 
Neuromyelitis optica (NMO) is an inflammatory autoimmune disorder of the CNS, 340 
characterised by pathogenic anti-aquaporin 4 antibodies (AQP-4Ab) and a generally worse 341 
prognosis than MS. The EBMT summarised 16 patients with refractory NMO treated with 342 
aHSCT (treated mainly with the ‘BEAM-ATG’ regimen); 3 cases remained progression- 343 
and treatment-free, whilst anti-AQP-4Ab antibodies persisted in 13 patients who required 344 
further treatments for relapses or disability progression70. Other data come from two case 345 
reports and a Chinese study in 21 patients with so-called opticospinal MS71-73. A recent 346 
case report showed a sustained clinical, radiological and immunopathological NMO 347 
remission with rituximab treatment prior to aHSCT74. Recent data from Northwestern 348 
University support favourable clinical outcomes of aHSCT with the Cy-ATG regimen 349 
combined with rituximab, with clearance of anti-AQP-4Ab75. 350 
 351 
4.3.5 Other immune-mediated neurological diseases 352 
Autoimmune encephalitis and other rare neurological diseases treated with aHSCT feature 353 
in the EBMT registry (see table 2), but published reports are limited. 354 
 355 
4.3.6 Systemic autoimmune diseases with neurological manifestations 356 
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In addition to autoimmune neurologic diseases, rheumatic diseases with CNS or PNS 357 
involvement and insufficient response to conventional immunusuppressive or biologic 358 
therapies represent a growing indication for aHSCT. Where there is a significant or 359 
predominant neurologibal component, they may be managed in neurology clinics.  360 
 361 
In a recently published study presenting the outcomes of aHSCT in 30 patients with SLE, 362 
10 patients suffered from neuropsychiatric manifestations, responding to aHSCT with 363 
cyclophosphamide, rabbit ATG and rituximab76. Similar results are obtained in smaller 364 
case series, which are summarized in a retrospective EBMT survey77. 365 
 366 
Systemic vasculitis may have neurological manifestations. Published literature on aHSCT 367 
for refractory BD with severe CNS involvement includes two patients from a retrospective 368 
data analysis from the EBMT registry78 and smaller series including one case undergoing 369 
first autologous followed by allogeneic HSCT79. All patients achieved complete remission, 370 
but one patient relapsed two years after HSCT. Data on Granulomatosis with Polyangiitis 371 
(GPA, formerly Wegener’s granulomatosis) with CNS involvement is limited to a single 372 
case reported to the EBMT registry, which achieved a complete response following 373 
conditioning with Cy/ATG and CD34-selected aHSCT80. Sjogren’s syndrome, polymyositis-374 
dermatomyositis and refractory coeliac disease (RCD) with neuromuscular manfestations 375 
have also been treated with aHSCT with favourable responses reported61,81-85. 376 
 377 
Recommendations 378 
• Patients with refractory CIDP, MG, NMO, SPS and systemic autoimmune 379 
disease with neurological manifestations may be considered for aHSCT (level 380 
CO/II).  381 
 382 
  
 
16
5. Autologous HSCT procedure 383 
5.1 General principles 384 
5.1.1 Centre experience and accreditation  385 
Autologous HSCT is an intensive procedure with a level of immediate transplant-related 386 
risks and other toxicities. Registry studies support a positive impact of JACIE 387 
accreditation86 on PFS, whilst the centre experience in ADs resulted in a statistically 388 
significant improvement of TRM, PFS and overall survival15,21. Such improvement is likely 389 
related to progressively improved patient selection, a dedicated pattern of care and the full 390 
integration between the HSCT and disease specialists. Experience is important as 391 
conditioning regimens used in aHSCT in ADs induce more profound immunosuppression 392 
than in haemato-oncological indications due to ATG, with a higher incidence of acute 393 
reactions, viral reactivations and infections. In addition, administration of DMTs before 394 
aHSCT may have an impact on the graft characteristics and immune reconstitution and 395 
further studies are required. There is a need for an extended competency and package of 396 
care for neurological patients, including specific pre-transplant work-up with attention to 397 
cardio-respiratory function, specific neurological supportive care measures, prolonged 398 
infective monitoring after the procedure, consideration of physiotherapy/rehabilitation26. 399 
Centre experience and accreditation may improve patient care and outcomes via 400 
implementation of specific staff training, procedures and audit in the institutional quality 401 
management system21,86. 402 
 403 
Recommendations 404 
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• Autologous HSCT should be delivered in transplant units that provide high 405 
quality care and are accredited by the JACIE or equivalent organisations 406 
(level II) 407 
• Units should be experienced with close collaboration between HSCT and 408 
neurology specialists throughout the patient journey including medium- and 409 
long-term follow up (level II)  410 
 411 
5.1.2 Multidisciplinary teams (MDTs) and patient consent 412 
Any decision to proceed must assess the balance of benefits and risks particularly in terms 413 
of reversibility or stabilization of disability and other neurological features. Decision-making 414 
requires critical multidisciplinary input from neurology and haematology specialities and 415 
may also involve other core members, such as nursing and professions allied to medicine 416 
(PAMs).  417 
Informed consent should be obtained for all phases of the transplant procedure, A frank 418 
discussion about potential risks, including TRM risk, transient worsening of function and 419 
other early and late transplant-related toxicities is an essential part of the consent process. 420 
The discussion should also include the risk-benefit of alternative treatments, including 421 
DMTs. Patients with childbearing potential should be counselled appropriately as 422 
temporary or permanent ovarian/testicular failure and infertility following aHSCT are known 423 
risks87,88. Fertility preservation strategies should be discussed. All patients should be 424 
invited to provide separate consent for submission of their anonymised/pseudonymised 425 
personal data to the EBMT, or equivalent, registry in accordance with relevant data 426 
protection and other regulations.  427 
5.2 Transplant technique 428 
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A variety of transplant techniques have been used, both in mobilization and conditioning 429 
(table 3). In accordance with previous EBMT guidelines21,26, two ‘intermediate-intensity’ 430 
conditioning regimens have been used most commonly in MS: BEAM-ATG and 431 
cyclophosphamide 200 mg/kg + ATG (Figure 3.2). Data on transplant technique for 432 
aHSCT in other immune-mediated neurological disorders outside MS is limited and 433 
heterogeneous. 434 
5.2.1 Pre-transplant ‘wash-out’ 435 
Prior to mobilisation, DMTs and other immunomodulatory drugs should be discontinued as 436 
early as possible, which may help minimize risks and inhibitory effects on successful 437 
mobilization. ‘Wash-out’ periods, commonly used in neurological practice for switching 438 
between DMTs, aim to reduce the risks of PML and other infections89. There is no 439 
consensus to support duration of wash-out periods. The following ‘wash-outs’ are 440 
examples; at least 6 weeks for dimethyl fumarate, fingolimod and natalizumab, and 6 441 
months for alemtuzumab, ocrelizumab and cladribine given the more profound 442 
lymphopenia and risk of infection. Accelerated elimination should be considered in patients 443 
on teriflunomide (https://www.aubagiohcp.com/content/pdf/drug_elimination_guide.pdf). 444 
No wash-out is necessary for interferon and glatiramer acetate. There have been no 445 
reports of PML following aHSCT in current EBMT registry data, but CSF JCV-PCR should 446 
be done on patients transitioning from natalizumab if they have high JCV antibody Index. 447 
Steroid pulses may be used to reduce the risk of relapses during the wash-out period. 448 
5.2.2 Peripheral blood stem cell [PBSC] mobilization and leukapheresis 449 
Most patients treated for AD have received priming doses of cyclophosphamide of 2–4.5 450 
g/m2 with uromixetan (Mesna) and/or cautious hyperhydration followed by G-CSF 5–10 451 
μg/kg prior to leukapheresis26,29-38,41. Administration of G-CSF alone may induce disease 452 
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flare, but its combined administration with ‘priming’ chemotherapy usually prevents flares, 453 
reduces T cell numbers in the graft and improves PBSC yields90. There are no data in 454 
terms of efficacy, but cyclophosphamide at a dose of 2 g/m2 is likely to be safer than 455 
higher doses but potentially less effective in terms of both mobilization potential and 456 
disease control. The procedure can usually be carried out as an outpatient regimen, but in 457 
disabled patients hospital admission may be considered. The need for repeat harvest 458 
appears to be rare, with little data to support the need for off-licence use of plerixafor.  459 
In line with EBMT recommendations, the minimum dose of CD34+ cells for re-infusion is 460 
2.0 ×106/kg, although other generic recommendations have proposed 4-5 x106/Kg as the 461 
optimal dose91,92. Considering that MS and neurological disorders are non-malignant 462 
indications, it would be pragmatic to aim for 5 x 106/kg as an optimal target before 463 
freezing, with 2.0 x 106/kg as a minimum safety threshold. Doses higher than 8 x 106/kg 464 
are unlikely to improve the rate of engraftment and have a theoretical risk of increased T 465 
cell contamination of the graft. 466 
Neurological patients undergoing mobilization are at risk of febrile neutropenia during 467 
mobilisation, and, if fever occurs, there may be a related transient worsening of 468 
neurological function, referred to as the Uhthoff phenomenon93. Oral antibiotic prophylaxis 469 
should be considered with a rapid pathway for hospital readmission and treatment of fever 470 
including use of steroids. Where disability precludes rapid readmission, patients can be 471 
hospitalised for the mobilisation phase. 472 
5.2.3 Conditioning regimens (table 3) 473 
Previous EBMT ADWP recommendations recommended the use of ‘intermediate intensity’ 474 
regimens namely cyclophosphamide 200mg/kg with T-cell depleting serotherapy (most 475 
commonly ATG) as a generic regimen across ADs, and, for MS, ‘BEAM-ATG’, was 476 
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specifically recommended26. The use of ‘high intensity’ regimens, including total body 477 
irradiation (TBI) or busulfan were not recommended on grounds of short and long-term 478 
toxicity, whilst the ‘low intensity’ regimens were considered to be less efficacious21,26. 479 
Higher intensity regimens, such as the ‘BuCy-ATG’ regimen, are efficacious but have been 480 
associated with potentially serious side effects, including veno-occlusive disease34. TBI, 481 
with its greater short and long-term risks, including infections, secondary malignancies, 482 
NRM and EDSS progression possibly due to radiation neurotoxicity, is now rarely used, if 483 
at all, and was reported as ineffective in advanced MS94. Regimens of a lower intensity 484 
such as cyclophosphamide 120mg/kg with ATG seem to be associated with an increased 485 
rate of relapse95. There is experience in Mexico of a low intensity regimen where 486 
cyclophosphamide at 100mg/kg has been used prior to re-infusion with unfrozen PBSC, 487 
with and without post-transplant rituximab. However, long-term outcome data are 488 
limited96,97.  489 
Since the publication of the EBMT 2012 guidelines26, there has been an increase in the 490 
use of Cy-ATG regimen in MS whilst BEAM-ATG usage has also been maintained (figure 491 
3.2). At present, there is no comparative data as to the relative efficacy and safety of these 492 
two most commonly used intermediate-intensity conditioning regimens. Therefore, EBMT 493 
guidelines advocate using either of these two regimens for MS. The question of relative 494 
safety and efficacy between these two intermediate treatment regimens may be resolved 495 
through an ongoing EBMT registry analysis.  496 
With respect to T-cell depleting serotherapy, the majority of MS patients have been treated 497 
with rabbit ATG (rATG) from various sources (Thymoglobulin/Sanofi-Genzyme and 498 
Grafalon/Neovii). Despite potential immunomodulatory advantages in non-transplant 499 
settings98, the use of horse-ATG (hATG) has been limited compared with rATG and 500 
associated with a greater level of toxicity in one early study running from 2001-200699.  501 
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However, in a more recent study the safety of a specific type of hATG (ATGAM, Pfizer) 502 
was assured with outcomes comparable to recent data using rATG100. The choice of type 503 
and dose of rATG depend on availability and centre preference, but in the published 504 
literature has been most commonly polyclonal rATG of thymoglobulin type given in dose 505 
range of 5–7.5mg/kg. Higher serum levels and type of ATG have been linked with infection 506 
and other outcomes in allogeneic HSCT101-103 and non-transplant aplastic anaemia104 507 
settings, but this has not been systematically investigated in relation to autologous HSCT 508 
for ADs. Other forms of serotherapy, such as alemtuzumab, have been used, although 509 
data suggest a higher rate of complications including secondary autoimmunity33. Given the 510 
heterogeneity of types of ATG and other serotherapy, further evaluation of their use in 511 
conditioning regimens is urgently warranted. 512 
Although HSCT units are likely to be experienced in the administration of ATG, it requires 513 
special attention given the potential for severe allergic-type reactions. These risks can be 514 
minimised with pre-medication consisting of antihistamines, paracetamol and steroids 515 
along with consideration of graduated dosing regimens and slow infusion rates. Varying 516 
doses of methylprednisolone (up to 1000mg41) have been used as pre-medication, but a 517 
minimum of methylprednisolone 2mg/kg intravenously is recommended with a sufficient 518 
time interval (e.g. 30-60 minutes) before the start of the ATG infusion. As there is ongoing 519 
risk of ATG-related fever and other reactions after the infusion a tapering dose of oral or 520 
intravenous steroid is often used routinely, with breakthough febrile or other episodes 521 
treated with additional pulses of intravenous methylprednisolone (e.g. 250mg) whilst 522 
ensuring that infection is fully covered. 523 
5.2.4 CD34+ selection and other graft manipulation 524 
The question of graft manipulation is unclear and is confounded with inevitable but 525 
unquantifiable degree of in vivo depletion of T-cells and other immune effector cells when 526 
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ATG is included in the conditioning regimen. In MS, both unmanipulated and manipulated 527 
autologous grafts have been used. CD34+ selection has featured in some clinical trials, 528 
including in combination with the higher intensity BuCy-ATG regimen. Whether this 529 
contributes to the reported benefits and toxicity is unclear. An EBMT retrospective analysis 530 
failed to show benefit of graft manipulation in MS105, and use in most other ADs26. 531 
Moreoever, CD34+ selection may be associated with excess infection and the selection 532 
procedure adds significantly to the costs and logistics of aHSCT. In the absence of firm 533 
evidence of benefit, the recommendation is that CD34+ selection or other graft 534 
manipulation is not used outside a clinical trial setting in MS and other neurological 535 
diseases. 536 
5.2.5 Supportive care, nursing and rehabilitation aspects 537 
Most patients have nursing and supportive care (including transfusion) requirements 538 
common to patients undergoing aHSCT for other indications. The main difference in 539 
patients is the degree of baseline disability. In addition, the administration of conditioning 540 
chemotherapy and ATG with high-dose steroids and hyperhydration in most regimens 541 
requires close inpatient observations, including fluid and electrolyte balance. Twice-daily 542 
weighing is recommended. As some neurology patients are prone to seizures, some units 543 
incorporate prophylaxis against seizures during conditioning. The risk of potential physical 544 
and psychological side effects of high-dose steroids should be highlighted to both patients 545 
and nursing staff. 546 
Urinary bladder dysfunction is common in MS, and residual volumes of urine represent not 547 
only a risk of infection, but also a risk of retaining cyclophosphamide metabolite, acrolein, 548 
which may cause haemorrhagic cystitis. All patients should be assessed for residual 549 
volume with ultrasound and, if necessary, a urinary catheter should be in situ for the period 550 
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of cyclosphophamide administration. This should be accompanied by uromixetan (Mesna) 551 
as per departmental standard operating procedures. Patients with long-term indwelling 552 
catheters should be managed appropriately, with vigilance for the higher level of infection 553 
risk.  554 
Occurrence of fever may affect the physical and mental state of the patient, and increase 555 
nursing needs to a greater degree in MS than in most other febrile transplant patients. 556 
Causes include ATG reactions, sepsis, urinary infections and viral reactivations. Fever of 557 
any type may temporarily compromise neurological function, referred to as the Uhthoff 558 
phenomenon93, and sustained fever during the transplant period have been reported to 559 
affect long term efficacy33. Fever should be pro-actively managed appropriate to the 560 
clinical picture to induce rapid defervescence.  561 
Vitamin D may have an impact on health and immune responses in MS and HSCT, and, 562 
given that patients are hospitalised during HSCT, routine supplementation should be 563 
considered106.  564 
 565 
Assessment and planning for rehabilitation should be performed prior to the transplant, for 566 
both the inevitable deconditioning effect of the aHSCT procedure and specific to 567 
neurological function of the patient. This area is currently the subject of a detailed EBMT 568 
ADWP review and guidance. 569 
 570 
Recommendations 571 
• All patients should be discussed within a multidisciplinary team (level III). 572 
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• Informed written consent, including discussions regarding alternative 573 
therapeutic options, should be obtained in accordance with national and local 574 
regulatory and legal requirements (level III).  575 
• Cyclophosphamide 2g/m2 and G-CSF 5-10 μg/kg is recommended for 576 
mobilization as it is likely to be sufficient for successful mobilization, prevent 577 
flare and be potentially safer than higher doses (level II).  578 
• For leukapheresis, an optimal target CD34+ cell dose is 5 x106/kg before 579 
freezing, with 2 x106/kg as a minimum safety threshold (level II). 580 
• For conditioning, the use of ‘intermediate-intensity’ regimens namely 581 
cyclophosphamide 200mg/kg + ATG or ‘BEAM’ + ATG are recommended 582 
(level II). 583 
• The use of ‘high-intensity’ regimens, including TBI or busulfan, should be 584 
restricted to study protocols in highly selected patients.  585 
• De-escalated regimens may be less efficacious, but the balance of benefits 586 
and risks of such regimens should be established with clinical trials (level II). 587 
• In the absence of high quality data in other immune-mediated neurological 588 
diseases, aHSCT technique should reflect the practice in MS depending on 589 
the experience of the transplant unit i.e. use of the EBMT recommended 590 
‘generic’ regimen of cyclophosphamide 200 mg/kg + ATG or BEAM-ATG 591 
(choice depending on the experience of the transplant unit) with the addition 592 
of B-cell depleting monoclonal antibodies (such as rituximab) when the 593 
disease origin includes a relevant antibody-mediated component (level II). 594 
• In the absence of firm evidence of benefit, CD34+ selection or other graft 595 
manipulation should not be used outside a clinical trial setting (level II). 596 
  
 
25
• Teams should be trained and competent with management of complications 597 
of the transplant regimen used in MS and other immune-mediated 598 
neurological diseases, including administration of and reactions to ATG and 599 
prevention and prompt management of fever in this context (level III). 600 
• Given the deconditioning effect of the aHSCT procedure combined with 601 
neurological disability highlight rehabilitation requirements should be 602 
assessed before and during the transplant admission and in place at the time 603 
of discharge (level III).   604 
 605 
6. Early and late post-transplant follow up  606 
Autologous HSCT may be associated with both early and late complications or ‘late 607 
effects26,107.  608 
 609 
6.1 Post-discharge monitoring and early post-transplant complications 610 
The use of aHSCT in neurological disorders has key differences compared to other 611 
common indications, notably related to the neurological condition themselves and degree 612 
of immunosuppression108. Post-discharge monitoring is predominantly focused on infection 613 
in the first months after aHSCT with prophylaxis as per centre protocols akin to allo-HSCT 614 
recommended. Generally oral prophylaxis should cover fungal infections (with an azole) 615 
for 3 months and herpes virus (with aciclovir) and pneumocystis infection for a minimum of 616 
6 months post-aHSCT, with many units extending to 12 months. Viral reactivation is 617 
important so PCR-based EBV/CMV monitoring is mandated during first 100 days. CMV re-618 
activation occurs at a greater rate and cases of CMV infection have been reported. EBV 619 
reactivation usually resolves spontaneously, but may need treatment with rituximab and 620 
may be associated with neurological events and de-novo paraproteinemia109. Immune 621 
monitoring of T- and B-cell subsets and immunoglobulin levels/electropheresis is 622 
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recommended on a 3-monthly basis in the first year and then annually in order to guide 623 
infection prophylaxis and detect paraproteinaemia110.  624 
 625 
Transient alopecia and amenorrhoea are common adverse effects, but menstrual function 626 
may recover especially in younger patients (<30 years of age)88. Haemorrhagic 627 
complications (e.g. gastrointestinal bleeding, hemorrhagic cystitis) have been reported.  628 
 629 
6.2 Late Effects/long-term complications 630 
International guidelines and recommendations cover screening and management of ‘late 631 
effects’ following HSCT107,111. Late effects following aHSCT may result from the transplant 632 
regimen and altered post-transplant immune reconstitution, but may also be driven by pre-633 
treatment of the underlying neurological disease. Since 2012 ‘late effects’ follow-up has 634 
been highlighted in the EBMT ADWP guidelines26, but limited data is available on the 635 
frequency and nature of late effects following aHSCT above what would be expected in the 636 
general population, and also what would be expected in the MS population treated with 637 
DMTs44,112. Impact on gonadal function and fertility should have been covered counselling 638 
related to the informed consent process, but should be revisited in routine follow-up of late 639 
effects87,88. Other recognised late effects include secondary autoimmunity (up to 10%) 640 
either de novo or within the spectrum of the original AD41,113-115, endocrinopathy 33,41 and 641 
late cancers 15,35. Concurrent AD is not infrequent and an appropriate screening (e.g. 642 
thyroid function) at baseline is mandatory. Although data is limited, the risk of PML 643 
appears low, with no current reports post-aHSCT, including in over 1400 patients treated 644 
for MS in the EBMT registry despite the frequent use of DMTs prior to transplantation 645 
(table 1). Late effects are the subject of ongoing EBMT retrospective studies, but in the 646 
meantime, it is important that systematic screening is undertaken in accordance with 647 
current recommendations for late effects26,107. 648 
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6.3 Post-transplant vaccinations 649 
Vaccination post-HSCT is a balance between reducing the risk of infection but comes with 650 
with a theoretical risk of triggering immune events, which is a concern in the setting of 651 
ADs116,117. Vaccination practice varies118, but in general, only vaccinations with live 652 
attenuated viruses are considered to pose a higher risk of inducing a relapse of MS, and 653 
these are generally avoided in routine post-transplant vaccination schedules. However, 654 
there is no clear-cut data to support the reactivation of MS or other ADs following aHSCT 655 
and therefore CIBMTR-EBMT, IDSA and ECIL recommendations should be followed with 656 
a case-by-case discussion with patients107,117,119. Measurements of specific antibody titres 657 
may be helpful in deciding whether to vaccinate or not117. A standard-of-care post-658 
transplant routine vaccination programme may be based on IDSA and ECIL guidelines as 659 
follows: pneumococcal conjugate vaccine at 3, 4 and 5 months, followed by conjugate HIB, 660 
DTP and inactivated polio vaccine at 6, 7 and 8 months and pneumococcal polysaccharide 661 
vaccine at one year. Later patients who are not on immunosuppressive therapy (e.g. for 662 
relapse) should have serology for measles and varicella tested at 24 months and those 663 
who are negative should be immunised with 2 doses of MMR and varicella vaccine at least 664 
4 weeks apart as per routine practice. Patients should also have an annual Influenza 665 
vaccine.  666 
 667 
6.4 Neurological follow-up and management of disease activity post-transplant 668 
The disease course after aHSCT should be monitored by regular neurological follow-up, 669 
with clinical assessments, imaging and immune markers in blood or cerebrospinal fluid 670 
(CSF) appropriate to the disease. In MS, NEDA can be assessed based on the clinical 671 
assessment and Gd enhanced MRI of brain and/or spine, which is required at regular 672 
intervals post-transplant (at 6 months post-transplant and yearly afterwards). Ongoing 673 
rehabilitation and other symptomatic care should be provided as appropriate. Currently, 674 
  
 
28
there is no consensus about the management of patients who develop disease activity 675 
after aHSCT, including re-introduced DMTs and second aHSCT.  676 
 677 
Recommendations 678 
• Post-discharge monitoring should be primarily focused on prophylaxis and 679 
management of infection in the first 3-6 months after aHSCT. Antibiotic 680 
prophylaxis should be given as per centre protocols, but generally oral 681 
prophylaxis should cover fungal infections (with an azole) for 3 months and 682 
herpes virus (with aciclovir) and pneumocystis infection for a minimum of 6-683 
12 months post-HSCT (level III).  684 
• PCR-based CMV monitoring is recommended during first 100 days post-HSCT 685 
and re-activations should be treated according to institutional protocols, 686 
similar to allogeneic HSCT practice (level III).  687 
• PCR-based EBV monitoring is recommended during first 100 days post-HSCT 688 
and reactivations managed with imaging and LDH, with rituximab considered 689 
on an individual basis (level III).  690 
• Immune monitoring of T- and B-cell subsets and immunoglobulin 691 
levels/electropheresis is recommended on a 3-monthly basis in the first year 692 
and then annually in order to guide infection prophylaxis and detect 693 
paraproteinaemia (level II). 694 
• Centres should ensure systems are in place to provide long-term follow-up. 695 
Annual simultaneous follow-up consultation of the neurology and HSCT 696 
specialists is recommended. If patients are discharged from the transplant 697 
centre for medium- and long-term follow-up under the referring neurologist, 698 
annual follow-up should be a standard of care and the contact details should 699 
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be made available to transplant centre data managers and/or the registry 700 
(level III). 701 
• Patients who develop recurrence of disease activity after aHSCT should be 702 
managed on an individual case basis. In general, assessment of risk:benefit, 703 
including cumulative toxicities of new and re-introduced DMTs should a 704 
consideration (level III).  705 
 706 
7. Mechanisms of action 707 
Autologous HSCT is performed with the premise to reconstitute, and ideally re-condition, 708 
the immune system towards a self-tolerant state by depleting the autoreactive 709 
immunologic memory with high-dose chemotherapy followed by a profound regeneration 710 
of a renewed and diverse immune system, i.e. ’immune reset’120-123.  711 
 712 
In MS, a range of mechanistic studies post-transplant have shown that the T-cell 713 
repertoire, particularly of CD4+ T-cells, may be almost completely renewed, its diversity 714 
increased and that new thymic output of T-cells is achieved following aHSCT124. The 715 
analysis of TCR repertoires by deep sequencing confirms that aHSCT induces the 716 
regeneration of circulating T-cell clones, more profoundly in the CD4+ T helper cell 717 
compartment125. Early post-transplant T-cell repertoire diversity is associated with 718 
complete clinical responses during the 5-year follow-up35,125. 719 
 720 
Other studies examined proinflammatory T-cell effector responses specifically, including 721 
Th17 cell frequency, the mRNA expression of their master regulator ROR[gamma]t and 722 
the production of the inflammatory cytokine IL-17A all decreased post-HSCT126. Several 723 
additional immune mechanisms that may contribute to the efficacy of aHSCT in MS have 724 
include depletion of peripheral blood mucosal-associated invariant T (MAIT) cells, 725 
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decrease of MS-associated inflammatory micro RNAs (miR-155, miR-142-3p, miR-16), 726 
along with increased immune T and NK regulatory cells and increased expression of 727 
immune checkpoint receptors and regulatory molecules such as PD-1, CTLA-4, GITR and 728 
TGF-b1127. 729 
 730 
Other neuro-inflammatory diseases have not been studied to any significant extent in the 731 
context of immune reconstitution and further research is warranted. The collection of 732 
cellular, serum, plasma and CSF samples at baseline, during the immunosuppression-free 733 
remission and at relapse/progression for mechanistic and pathogenetic studies in 734 
accordance with regulatory requirements for tissue banking and ADWP guidelines is 735 
recommended110.   736 
 737 
Recommendations 738 
• Systems for biobanking should be developed alongside clinical trials, 739 
routine treatments and registry data in order to support mechanistic and 740 
pathogenetic studies in MS and neuroinflammatory diseases (level III). 741 
 742 
8. Developmental indications: allogeneic HSCT and cell therapy in immune-743 
mediated neurological diseases 744 
 745 
8.1 Allogeneic HSCT  746 
Allogeneic HSCT represents an attractive option for patients with refractory ADs, offering 747 
the advantage of complete eradication of autoreactive cells combined with the 748 
regeneration of a healthy immune system tolerant to autoantigens. However, because of 749 
its significantly higher level of NRM risk, allo-HSCT has rarely been used in the treatment 750 
of ADs21,26,24,128. Only anecdotal data are available to date for allo-HSCT in 751 
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neuroinflammatory ADs, notably severe NMO, where sustained clinical benefit with 752 
resolution of detectable anti-AQP-4Ab has been reported129.   753 
 754 
Major changes have occurred in the field of allo-HSCT130-131 including targetted reduced-755 
intensity conditioning and post-transplant tolerising regimens, improved patient and donor 756 
selection and better supportive care open up the use of alloHSCT in ADs. Further clinical 757 
studies with these modern approaches are warranted. 758 
 759 
Recommendations 760 
• Centres performing allogeneic HSCT should have appropriate experience 761 
and JACIE accreditation or equivalent (level II). 762 
• Allogeneic HSCT for immune-mediated neurological diseases is 763 
developmental and ideally should be performed in a prospective clinical 764 
study (level III). 765 
• In the absence of data, conditioning regimens and other allogeneic HSCT 766 
technique should reflect the practice in other non-malignant diseases 767 
(level III). 768 
 769 
8.2 Mesenchymal Stromal Cells (MSC) and other experimental cellular therapies  770 
A range of pre-clinical data and early phase trials provide support for mesenchymal 771 
stromal cells derived from autologous and allogeneic sources as immunomodulators with 772 
the potential to neuroprotect and foster remyelination endogenous neurogenesis and 773 
differentiation in neural cells132. Since 2007, over 15 small studies exploring the feasibility 774 
and safety of MSC transplantation in multiple sclerosis have been published133. These 775 
studies involved differing patient populations, cell products, and routes of administration. 776 
All were underpowered for drawing conclusions on efficacy but reported an overall 777 
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favourable safety profile. The results of two more similar studies (ACTiMuS, SIAMMS-II 778 
are awaited and a larger randomized, double blind, cross-over phase I/II clinical trial 779 
(MESEMS) is ongoing134-136. Haematopoietic stem cells genetically manipulated to induce 780 
self-tolerance against myelin epitopes have also been explored137, which may have 781 
potential at improving long term remissions following aHSCT. Non-HSCT cell therapies for 782 
autoimmune diseases should be considered a developmental indication as there limited 783 
evidence to support administration outside a clinical trial. Generally, there is a need to 784 
safeguard vulnerable patients against unjustified hope whilst promoting further clinical 785 
trials and basic research28. Centres should be accredited according to appropriate JACIE 786 
standards relating to immune effector cell (IEC) therapies86. 787 
 788 
Recommendations  789 
• Routine treatment with MSC and other cell therapy is not recommended as 790 
there is insufficient evidence as to safety and efficacy in both the 791 
inflammatory and progressive phases of MS (level III).  792 
• Patients with MS and other immune-mediated neurological disorders should 793 
only be treated with MSCs in clinical trials. Centres should be accredited 794 
according to appropriate JACIE standards relating to immune effector cell 795 
therapies (level III). 796 
 797 
9. Future development of HSCT in MS and neuro-inflammatory diseases  798 
9.1 Data reporting to the EBMT Registry 799 
Data reporting to the EBMT Registry (and equivalent international registries) has been 800 
fundamental to building the knowledge base of HSCT in AD and providing the basis for 801 
prospective studies21,26. A major upgrade of the EBMT Registry across all indications is 802 
centred around a mandatory core dataset maximising capture of essential data defining 803 
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the patient, procedure, disease, risks, and donor (if relevant), key time points and events 804 
required for risk stratification and benchmarking of outcomes. Alongside the core dataset, 805 
a modular system is available for defined projects attempting to address strategic research 806 
questions generated by the EBMT scientific council, working parties or other working 807 
groups. Modules can be used for retrospective data or prospective non-interventional 808 
studies. In addition, developments should facilitate the incorporation of non-HSCT 809 
treatments with the potential for direct data reporting from neurologists and other disease 810 
specialists. All of these aspects are especially relevant for HSCT in MS and other immune-811 
related neurological diseases diseases where the timelines for development of clinical 812 
manifestations, particularly evolution of disability, is often long, and evaluation of late 813 
effects may take many years.  814 
 815 
Transplant centre data managers are generally less familiar with ADs, and many patients 816 
are seen in departments outside the transplant centre. Complete data registration has 817 
proven more challenging for ADs than standard haematological and oncological 818 
indications for HSCT. Data managers should be adequately trained and supervised by 819 
relevant HSCT and neurological specialists and ideally neurological data reporting should 820 
be integrated by the referring neurologist and their teams. If aHSCT is to be integrated into 821 
neurological care pathways, it is vital that efficacy and safety are monitored as robustly as 822 
possible via HSCT centres or collaborating neurologists over the long-term. Aligning 823 
clinical databases with biobanked samples will allow greater understanding of mechanisms 824 
of action and improved risk stratification of patients.  825 
 826 
Recommendations 827 
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• Data relating to HSCT in MS and other neuro-inflammatory diseases 828 
should be routinely reported to EBMT or equivalent registry (level III). 829 
• Data managers should be adequately trained and supervised by relevant 830 
HSCT and neurological specialists (level III).   831 
• Systems for biobanking should be developed alongside clinical trials and 832 
registry data (level III). 833 
 834 
9.2 Statistical considerations for clinical studies 835 
Statistical approaches commonly used in other areas of HSCT practice are less easily 836 
applied to prospective clinical trials and retrospective studies in MS, where it is important 837 
to define appropriate target endpoints to assess the response to administered treatments, 838 
whether they are HSCT or other potent treatments. Fortunately, overall survival (OS) is 839 
high and all-cause mortality (including NRM) is rare following aHSCT. However, concepts 840 
of NRM, PFS and OS are commonly used in HSCT but are unusual to neurologists. 841 
Moreover, relapses independent of disease progression do not always represent a 842 
treatment failure. Progression of disability can be related to an advanced stage of the 843 
disease at HSCT and should not be considered as a treatment failure if not associated 844 
with recurrence of neuroinflammation.  845 
Given the growing evidence that an early therapy escalation in aggressive forms may 846 
prevent both the development of severe disability and the shift toward the progressive 847 
phase through the permanent abrogation of inflammatory activity in the CNS, a reliable 848 
assessment of treatment response must include both clinical and radiological metrics, as 849 
combined in ‘NEDA’ status8. Rate of NEDA in a set of patients at a given time from the 850 
treatment start and/or time to maintain a NEDA status are currently considered the most 851 
reliable assessment of treatment efficacy in MS and should be considered in any HSCT 852 
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trial39.40. Improvement in EDSS is an endpoint that has been increasingly used for 853 
aggressive therapies in MS and should be included among the endpoints to assess 854 
aHSCT, taking into account not only the magnitude of improvement levels but also its 855 
durability.   856 
In addition, validated health-related quality-of-life and neuropsychological instruments are 857 
important and easily achievable endpoints. Brain volume loss, optical coherence 858 
tomography (OCT), corneal confocal microscopy and PET imaging may increasingly 859 
provide more sophisticated means of quantifying efficacy in the clinical trial setting. 860 
Alongside efficacy, there is the question of the risks of late effects of aHSCT compared 861 
with modern DMTs, several of which may have been administered to patients prior to 862 
transplant. 863 
 864 
RCTs are the best means to establish the safety and efficacy of aHSCT versus alternative 865 
‘standard of care’. Although this approach may be feasible for aHSCT in MS, there will 866 
always be the challenge of ‘standard of care’ evolving as new DMTs emerge, especially if 867 
recruitment is slow. This was an issue in the MIST trial, where alemtuzumab became a 868 
standard of care in the years taken to complete recruitment for the trial41,138 and now 869 
ocrelizumab and cladribine currently provides similar competition for ongoing studies. In 870 
the rarer immune-mediated neurological disease indications RCTs are unlikely to be 871 
feasible, and other clinical trial designs may be more appropriate and ongoing 872 
retrospective studies and prospective non-interventional studies based around the EBMT 873 
registry (which is generally limited to patients HSCT only making comparison with standard 874 
of care difficult) along with other neurologically based registries, such as MSBase, may 875 
provide meaningful clinical data via prospective cohort studies and case–control studies. 876 
The recognition of potential bias and adjustment for all potential prognostic factors is 877 
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essential in any non-randomised settings in order to accommodate inevitable confounding 878 
factors and selection bias in choosing aHSCT over another treatment. 879 
Recommendations 880 
• Where feasible, HSCT for MS and other immune-mediated neurological 881 
diseases should be offered in a clinical trial.  882 
• In any study of MS and other immune-mediated neurological diseases, 883 
well-defined and validated parameters should be used to define response, 884 
progression and remission. For MS, the NEDA status is appropriate for 885 
this purpose and feasibly collected alongside other transplant data in the 886 
EBMT Registry (level III).  887 
• Magnitude and durability of EDSS improvement should be included as an 888 
endpoint for evaluating aHSCT in MS (level III). 889 
• Prospective non-interventional studies provide an alternative and 890 
pragmatic means of increasing clinical knowledge, while eliminating bias 891 
associated with retrospective studies (level III).  892 
• Although prospective studies are preferred, significant challenges should 893 
be recognized in their application to HSCT especially in the rare immune-894 
mediated neurological diseases. When clinical trials are not available then 895 
patient data should be sent to EBMT (or equivalent) registry (level III).  896 
 897 
 898 
9.1.3 Clinical trials of aHSCT in MS 899 
While it is now clear that clinical and MRI activity in patients with highly active RRMS may 900 
be suppressed with the use of aHSCT in a sustained manner, there remains a need for 901 
comparative studies that randomize patients to aHSCT versus other high-efficacy 902 
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therapies, particularly the more recently introduced alemtuzumab, ocrelizumab and 903 
cladribine, where there is are highly relevant research questions regarding relative 904 
reported rates of NEDA, albeit across prospective trials in RR-MS with varying eligibility 905 
criteria, as summarised in table 4. Current clinical trials, designed with a view to answer 906 
these and other questions, are summarised in table 5.  907 
 908 
Another question is to whether aHSCT may offer benefit for the progressive forms of MS, 909 
which may continue to have elements of ongoing and resistant neuro-inflammation. In the 910 
last two decades, a large number of patients with progressive disease have been treated 911 
with aHSCT and there is some evidence for reduced relapse rates and clinical 912 
stabilisation, but it is difficult to interpret these studies due to the lack of control groups15,16, 913 
20, 31,38,47. Further RCTs are required to assess the therapeutic benefit of aHSCT in SPMS 914 
and PPMS with evidence of significant inflammation.  915 
 916 
9.4 Public health system delivery of HSCT in MS and immune-mediated neurological 917 
diseases  918 
At a public health level, economic evaluation is a central consideration in delivering 919 
aHSCT for MS and neuroinflammatry diseases. MS results in a large burden on both the 920 
health and social care systems as well as the wider exchequer. The costs incurred range 921 
from direct costs related to treatment with DMTs, but also reduces long-term quality of life 922 
and leads to unemployment, progressive disability and eventually dependency, high rates 923 
of unemployment with substantial impact on the affected individual and their carers with 924 
reduced quality of life and on the health care service. Compared with ongoing repeated 925 
treatments with modern DMTs, aHSCT is a ‘one-off’ treatment, for which, therapeutic 926 
benefits last for many years in appropriately selected patients. Favorable cost-927 
effectiveness ratio in MS patients showing a sustained response to HSCT over some 928 
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DMTs has been reported142-144. However, for accurate and up-to-date evaluations, health 929 
economic evaluation should be combined with prospective clinical trials. There is great 930 
variability in funding for aHSCT in MS and other ADs across EBMT countries, and further 931 
evaluations are needed to provide equitable access according to clinical benefit as close to 932 
patients’ homes as feasible. 933 
Recommendations 934 
• Health economic evaluations are central to informing the effective delivery 935 
of HSCT for MS and other neurological disorders across various health 936 
services (level III). 937 
• Engagement with public health authorities and other payers is essential 938 
across health services, enabling treatment and coordination of early- and 939 
long-term follow up as close to patients’ homes as feasible (level III).  940 
 941 
10. Conclusions 942 
We have reviewed the evidence for aHSCT for a range of immune-mediated neurological 943 
diseases which may respond to aHSCT when other standard treatments have failed, or 944 
are deemed likely to fail because of poor-prognostic features. The evidence for 945 
effectiveness is highest in highly active RRMS where there is growing evidence from large 946 
registry studies and a prospective phase III RCT supporting the safe delivery of aHSCT 947 
with long-term clinical and MRI remissions observed in a majority of patients (S/I). In 948 
progressive MS and other neuro-inflammatory indications data is heterogeneous (CO/II) 949 
and aHSCT should be delivered on a clinical trial, if available. The evidence for allogeneic 950 
HSCT is developmental (D/III). There is a need for clinical trials across all settings.  951 
Close co-operation between HSCT and neurological specialists in MS and 952 
neuroinflammation is critical. In addition to EBMT and national societies, the support of 953 
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national and international MS and neurological societies is also essential to achieve 954 
education, and ultimately acceptance and implementation of this one-off intensive 955 
approach to MS and other immune-related neurological diseases. Patient groups, such as 956 
the EBMT Patient Advocacy Committee and national MS and other patient associations 957 
are also important. Centres of specialization and experience will be required to support 958 
others in bringing HSCT appropriately into neurological clinical practice alongside modern 959 
DMTs. Standardization of practice will assist the support that experienced units can 960 
provide to less experienced units. At a public health level, health economic evaluations will 961 
be necessary to support decision making and optimise equitable access to evidence-962 
based treatments in publically-funded and private healthcare systems21,28.  963 
 964 
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Table 1. Summary of autologous HSCT for MS and other immune-
mediated neurological diseases in the EBMT Registry, July 2019  
 
  N (%) 
Multiple sclerosis 1446 (92.9) 
    Malignant/Agressive 37 (2.7) 
    Progressive (primary or secondary) 617 (45.8) 
    Relapsing remitting 693 (51.4) 
    Missing (n=99, 6.8%)   
Other neurogical disease 105 (7.1) 
    Chronic Inflammatory Demyelinating Polyneuropathy  54 (3.5) 
    Neuromyelitis optica 17 (1.1) 
    Myasthenia gravis 9 (0.6) 
    Encephalitis 5 (0.3) 
    Stiff Person Syndrome 4 (0.3) 
    Other neurological diseases 21 (1.3) 
 
Figure 1. EBMT ADWP activity – Autologous HSCT for MS, other immune-mediated neurological 
diseases and other autoimmune diseases by year, 1994-2018 (N=2766) 
 
 
 
 
 
Figure 2. EBMT registry: Overall national activity in autologous HSCT indicated for MS, other 
immune-mediated neurological diseases and other autoimmune diseases by country, 1994-2018 
(N=2766) 
 
 
 
 
 
Figure 3.1 EBMT registry: Relative activity according to reported multiple sclerosis type: RR-MS 
versus progressive MS (SPMS/PPMS) versus aggressive/malignant MS 
 
 
 
 
Figure 3.2 Trends in transplant conditioning used for autologous HSCT in Multiple Sclerosis: BEAM-
ATG versus Cy-ATG (EBMT Registry 1995-2018) 
 
 
Table 2. Summary of recommendations for HSCT and cellular 
therapy in Multiple Sclerosis and other immune-mediated 
neurological diseases 
  
 Autologous 
HSCT  
MSD Allo 
HSCT  
MUD Allo 
HSCT 
MMAD 
Allo HSCT 
Cellular 
therapy  
Highly active relapsing remitting MS failing 
DMTs  
S/I D/III GNR/III GNR/III D/III 
Progressive MS with active inflammatory 
component  
CO/II D/III GNR/III GNR/III D/III 
Aggressive* (malignant) MS not previously 
treated with a full course of DMT  
CO/II D/III GNR/III GNR/III D/III 
Progressive MS without active inflammatory 
component 
GNR/III GNR/III GNR/III GNR/III D/III 
Paediatric MS  CO/II GNR/III GNR/III GNR/III D/III 
CIPD CO/II GNR/III GNR/III GNR/III D/III 
NMO CO/II D/III D/III D/III D/III 
MG CO/II GNR/III GNR/III GNR/III D/III 
SPS CO/II GNR/III GNR/III GNR/III D/III 
Systemic ADs  
e.g. SLE, vasculitis, Behcets disease, 
Sjogren’s syndrome, refractory coeliac 
disease with neurological manifestations 
CO/II GNR/III GNR/III GNR/III D/III 
 
*Aggressive MS as per Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, et al. Characterising aggressive 
multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1192–98. 
As updated by Duarte et al 2019, EBMT indications are classified in four categories, listed below, to describe the settings where 
these types of transplants ought to be performed. The strength of the evidence supporting the assignment of a particular 
category is graded in three levels: 
 
Grade I: 181 Evidence from at least one well-executed randomized trial. 
 
Grade II: Evidence from at least one well-designed clinical trial without randomization; cohort or case-controlled analytic studies 
(preferably from more than one centre); multiple time-series studies; or dramatic results from uncontrolled experiments. 
 
Grade III: Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports from 
expert committees. 
 
Standard of care (S): Indications categorised as S are reasonably well defined and results compare favourably (or are superior) 
to those of non-transplant treatment approaches. Obviously, defining an indication as the standard of care does not mean an 
HSCT is necessarily the optimal therapy for a given patient in all clinical circumstances. “Standard of care” transplants may be 
performed in a specialist centre with experience in HSCT and an appropriate infrastructure as defined by the 
JACIE guidelines. 
 
Clinical option (CO): The CO category applies to indications for which the results of small patient cohorts show efficacy and 
acceptable toxicity of the HSCT procedure, but confirmatory randomised studies are missing, often as a result of low patient 
numbers. The broad range of available transplant techniques combined with the variation of patient factors such as age and co-
morbidity makes interpretation of these data difficult. Our current interpretation of existing data for indications placed in this 
category supports that HSCT is a valuable option for individual patients after careful discussions of risks and benefits with the 
patient but that for groups of patients the value of HSCT needs further evaluation. Transplants for indications under this 
heading should be performed in a specialist centre with major experience in HSCT with an appropriate infrastructure as defined 
by JACIE guidelines. 
 
Developmental (D): Indications have been classified as D when the experience is limited, and additional research is needed to 
define the role of HSCT. These transplants should be done within the framework of a clinical protocol, normally undertaken by 
transplant units with acknowledged expertise in the management of that particular disease or that type of HSCT. Protocols for 
D transplants will have been approved by local research ethics committees and must comply with current international 
standards. Rare indications where formal clinical trials are not possible  should be performed within the framework of a 
structured registry analysis, ideally an EBMT non-interventional/observational study. Centres performing transplants under this 
category should meet JACIE standards. 
 
Generally not recommended (GNR): The GNR category comprises a variety of clinical scenarios in which the use of HSCT 
cannot be recommended to provide a clinical benefit to the patient, including early disease stages when results of conventional 
treatment do not normally justify the additional risk of a HSCT, very advanced forms of a disease in which the chance of 
success is so small that does not justify the risks for patient and donor, and indications in which the transplant modality may not 
be adequate for the characteristics of the disease. A categorization as GNR does not exclude that centres with particular 
expertise on a certain disease can investigate HSCT in these situations. Therefore, there is some overlap between GNR and D 
categories, and further research might be warranted within prospective clinical studies for some of these indications. 
  
 
Table 3. Categorisation of conditioning regimens used for 
autologous HSCT, with examples used in MS and other immune-
mediated neurological diseases20,21,26 
  
Intensity  Examples of conditioning regimens 
High  Total body irradiation (TBI), cyclophosphamide and ATG 
 
 
 Busulfan, cyclophosphamide and ATG (BuCyATG) 
 
Intermediate  
(myeloablative) 
Carmustine (BiCNU) 300mg/m2, etoposide 800mg/m2, 
cytarabine- arabinoside 800mg/m2 and melphalan 
140mg/m2 (BEAM) and ATG (BEAM-ATG) 
 
 
Intermediate  
(lymphoablative/non-
myeloablative) 
 
Cyclophosphamide 200mg/Kg and rabbit ATG (Cy-ATG)
 
 
Low  Chemotherapy only* regimens e.g. single agent 
cyclophosphamide 100mg/kg for mobilisation and 
repeated 100mg/kg for conditioning (without rituximab) 
96,97
 
  
 
*Addition of serotherapy (i.e. antibody therapy) to chemotherapy renders the regimen 
‘intermediate-intensity’).  
N.B. Please note doses are examples and the authors do not take responsibility for 
drug and doses administered which lies with individual authorised prescribers in 
HSCT units   
 
Table 4.  Mechanism of action and the relative rates of NEDA in prospective 
trials of high efficacy DMTs and autologous HSCT in RRMS  
  
Therapeutic  Mechanism of action  Rate of 
NEDA 
Ref 
Alemtuzumab Anti-CD52 monoclonal antibody 
 
39–32% at 2 
years  
44, 138, 
139 
 
Ocrelizumab 
 
Anti-CD20 monoclonal antibody 
 
48% at 96 
weeks  
 
140 
 
Cladribine 
 
 
Autologous 
HSCT with 
intermediate-
intensity 
conditioning 
 
Synthetic deoxyadenosine analogue 
 
 
Immune ablation and reconstitution 
Cy-ATG (with unmanipulated graft) 
 
 
BEAM-ATG (with CD34+ selected graft) 
 
47% at 96 
weeks 
 
 
93.3%, 
median follow 
up 2 years 
69.2% (EFS), 
median follow 
up 5 years  
 
141 
 
 
 
33 
 
 
35 
    
 
N.B. The trials differ in eligibility criteria and design, including prior DMT treatment and disease 
activity at study entry. The reader is referred to the original publications for more detailed comparison. 
 
Table 5. Currently active clinical trials of autologous HSCT in MS 
  
Trial/identifier  Description  Centres/countries
RAM-MS 
NCT03477500 
Phase III RCT of autologous HSCT (Cy-
ATG) versus alemtuzumab 
 
Scandanavia, 
Netherlands  
STAR-MS 
 
 
 
BEAT-MS 
 
 
MOST 
NCT03342638 
  
Phase III RCT of autologous HSCT (Cy-
ATG) versus alemtuzumab or 
ocrelizumab 
 
Phase III RCT of autologous HSCT 
(BEAM-ATG) versus standard of care 
  
Phase III RCT autologous HSCT (Cy-
ATG versus Cy-ATG + intravenous 
immunoglobulin) 
 
UK  
 
 
 
US predominantly 
(NIH-led) 
 
Northwestern 
University, US 
 
COAST 
 
Phase II autologous HSCT (Cy-ATG) 
 
Germany   
NET-MS 
(Italian 
collaborative) 
 
 
Phase II autologous HSCT (BEAM-ATG) 
 
 
 
 
Italy 
 
 
 
 
Swiss aHSCT 
Registry Study 
 
 
 
Mexican open 
label study 
NCT02674217 
 
Open study of autologous hematopoietic 
stem cell transplantation in patients with 
RRMS and progressive forms of MS (5 
year duration) 
 
Outpatient Hematopoietic Grafting in 
Patients With Multiple Sclerosis 
Employing Autologous Non-
cryopreserved Peripheral Blood Stem 
Cells: A Feasibility Study 
 
 
University Hospital 
Zurich, Switzerland
 
 
 
Clinica Ruiz, 
Puebla, Mexico 
 
 
 
